ONCORE™ is Handa’s proprietary drug delivery technology that was developed to improve the patient compliance and safety of the Tyrosine Kinase Inhibitor (TKI) class of oncology drugs.
● ONCORE™ employs a unique salt / formulation that is capable of minimizing the pH effect of the drug in the gastrointestinal tract, which enables:

￭ Elimination of the drug’s food effect.

￭ Elimination of the acid reducing agent/Proton Pump Inhibitor (PPI) restrictions while taking the drug, which is prevalent with the TKI class.

● ONCORE™ can also be used to improve a TKI’s systemic absorption, resulting in:

￭ Dose reduction.

￭ Reduced exposure of the drug in the gastrointestinal (GI) tract.

￭ Increased safety profile to improve patient compliance.